Published in Int J Oncol on January 23, 2013
Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Int J Oncol (2014) 0.93
Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican‑3‑derived peptide. Int J Oncol (2013) 0.81
Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects. Immunotherapy (2014) 0.78
A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma. Mol Ther (2017) 0.75
Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model. Biochem Biophys Rep (2016) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol (1997) 2.98
Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun (2003) 2.78
Glypicans. Genome Biol (2008) 2.76
Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res (2005) 2.68
Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res (2012) 1.84
Glypicans in growth control and cancer. Glycobiology (2001) 1.75
High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology (1994) 1.74
Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res (2006) 1.64
Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology (2001) 1.61
A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res (2006) 1.48
Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res (2004) 1.32
T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res (2003) 1.24
Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma. Hepatology (2011) 1.24
HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells. Cancer Sci (2011) 1.23
A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer (2010) 1.15
Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay. Eur J Immunol (1994) 1.08
HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Int J Oncol (2008) 1.04
TAP2-defective RMA-S cells present Sendai virus antigen to cytotoxic T lymphocytes. Eur J Immunol (1993) 1.03
Immunotherapy of hepatocellular carcinoma. J Hepatol (2006) 1.00
Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10. Cancer Res (2006) 0.93
Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy. Cancer Immunol Immunother (2012) 0.91
Prediction of HLA class I-restricted T-cell epitopes of islet autoantigen combined with binding and dissociation assays. Autoimmunity (2012) 0.89
A glypican-3-derived peptide vaccine against hepatocellular carcinoma. Oncoimmunology (2012) 0.88
HLA-A*0201-restricted CTL epitope of a novel osteosarcoma antigen, papillomavirus binding factor. J Transl Med (2009) 0.86
Identification of HLA-A*0201- and A*2402-restricted epitopes of mucin 5AC expressed in advanced pancreatic cancer. Pancreas (2011) 0.83
Identification of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from the lung carcinoma antigen, Lengsin. Int J Oncol (2011) 0.82
Identification and functional studies of HLA-A0201 restricted CTL epitopes in the X protein of hepatitis B virus. Acta Virol (2011) 0.80
Identification of the H2-Kd-restricted cytotoxic T lymphocyte epitopes of a tumor-associated antigen, SPARC, which can stimulate antitumor immunity without causing autoimmune disease in mice. Cancer Sci (2008) 0.78
Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes. Eur J Immunol (2009) 0.78
Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res (2012) 1.84
Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res (2006) 1.64
Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci (2009) 1.64
Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol (2009) 1.29
HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells. Cancer Sci (2011) 1.23
HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL. Int J Cancer (2008) 1.10
Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression. Cancer Lett (2009) 1.07
Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis. Clin Cancer Res (2004) 1.04
HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Int J Oncol (2008) 1.04
Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma. Cancer Sci (2011) 1.03
Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines. Oncol Rep (2011) 1.00
Drug-induced CD30+ T cell pseudolymphoma. Eur J Dermatol (2009) 0.99
Genetically manipulated human embryonic stem cell-derived dendritic cells with immune regulatory function. Stem Cells (2007) 0.98
Risk factors for acute renal injury in living donor liver transplantation: evaluation of the RIFLE criteria. Transpl Int (2013) 0.98
Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes. Int J Oncol (2011) 0.96
Acute Generalized Exanthematous Pustulosis Caused by Faropenem: A Possible Pathogenetic Role for Interleukin-23. Acta Derm Venereol (2016) 0.95
Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10. Cancer Res (2006) 0.93
Heat shock protein 105 is overexpressed in a variety of human tumors. Oncol Rep (2003) 0.92
Single-cell analysis of T-cell receptor repertoire of HTLV-1 Tax-specific cytotoxic T cells in allogeneic transplant recipients with adult T-cell leukemia/lymphoma. Cancer Res (2010) 0.92
Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy. Cancer Immunol Immunother (2012) 0.91
Postoperative serum alpha-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma. Oncol Rep (2010) 0.90
Cholinergic urticaria: studies on the muscarinic cholinergic receptor M3 in anhidrotic and hypohidrotic skin. J Invest Dermatol (2010) 0.90
Synthetic small interfering RNA targeting heat shock protein 105 induces apoptosis of various cancer cells both in vitro and in vivo. Cancer Sci (2006) 0.90
Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: an autopsy case. Hum Vaccin Immunother (2013) 0.89
The vIL-10 gene of the Epstein-Barr virus (EBV) is conserved in a stable manner except for a few point mutations in various EBV isolates. Virus Genes (2007) 0.88
Skin manifestations of adult T-cell leukemia/lymphoma: clinical, cytological and immunological features. J Dermatol (2014) 0.88
A glypican-3-derived peptide vaccine against hepatocellular carcinoma. Oncoimmunology (2012) 0.88
Peptide vaccines for hepatocellular carcinoma. Hum Vaccin Immunother (2013) 0.88
Pathogenesis of cholinergic urticaria in relation to sweating. Allergol Int (2012) 0.88
Silencing of secreted protein acidic and rich in cysteine inhibits the growth of human melanoma cells with G arrest induction. Cancer Sci (2009) 0.88
CD8+ CD56+ mycosis fungoides with an indolent clinical behaviour: case report and literature review. Acta Derm Venereol (2010) 0.86
Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation? J Gastroenterol (2013) 0.86
Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses. Clin Cancer Res (2004) 0.85
Decreased NKG2D expression on CD8+ T cell is involved in immune evasion in patients with gastric cancer. Clin Cancer Res (2007) 0.85
The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy. Int J Cancer (2010) 0.85
Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site. Cancer Res (2003) 0.85
Glypican 3 expression in tumors with loss of SMARCB1/INI1 protein expression. Hum Pathol (2012) 0.84
Differential expression of heat shock protein 105 in melanoma and melanocytic naevi. Melanoma Res (2008) 0.84
Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels. Clin Cancer Res (2005) 0.84
Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. J Hepatobiliary Pancreat Sci (2013) 0.84
Erosive pustular dermatosis of the scalp and leg associated with myasthenia gravis: A possible pathogenetic role for neutrophil-stimulating cytokines and chemokines. Acta Derm Venereol (2010) 0.84
Regression of intestinal adenomas by vaccination with heat shock protein 105-pulsed bone marrow-derived dendritic cells in Apc(Min/+) mice. Cancer Sci (2007) 0.83
Identification of beta2-microgloblin as a candidate for early diagnosis of imaging-invisible hepatocellular carcinoma in patient with liver cirrhosis. Oncol Rep (2010) 0.83
Risk factors for organ/space surgical site infection after hepatectomy for hepatocellular carcinoma in 359 recent cases. J Hepatobiliary Pancreat Sci (2013) 0.82
Peptide intra-tumor injection for cancer immunotherapy: enhancement of tumor cell antigenicity is a novel and attractive strategy. Hum Vaccin Immunother (2013) 0.82
Identification of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from the lung carcinoma antigen, Lengsin. Int J Oncol (2011) 0.82
Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican‑3‑derived peptide. Int J Oncol (2013) 0.81
Maculopapular-type drug eruption caused by entecavir. Eur J Dermatol (2011) 0.81
DNA vaccination of HSP105 leads to tumor rejection of colorectal cancer and melanoma in mice through activation of both CD4 T cells and CD8 T cells. Cancer Sci (2005) 0.80
Valsartan-induced drug eruption followed by CD30+ pseudolymphomatous eruption. Acta Derm Venereol (2010) 0.80
Multiscale fabrication of a transparent circulation type blood vessel simulator. Biomicrofluidics (2010) 0.79
Cleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restricted and tumor-specific CTLs in the majority of gastrointestinal cancer patients. Int J Cancer (2002) 0.79
Detection of glypican-3-specific CTLs in chronic hepatitis and liver cirrhosis. Oncol Rep (2009) 0.79
New surgical approach to large splenorenal shunt in living donor liver transplantation: diversion of SMV and SPV blood flow. J Gastrointest Surg (2012) 0.79
Selective capture and collection of live target cells using a photoreactive silicon wafer device modified with antibodies via a photocleavable linker. Langmuir (2012) 0.78
Accumulation of Epstein-Barr virus (EBV) BMRF1 protein EA-D during latent EBV activation of Burkitt's lymphoma cell line Raji. Microbes Infect (2006) 0.78
Identification of the H2-Kd-restricted cytotoxic T lymphocyte epitopes of a tumor-associated antigen, SPARC, which can stimulate antitumor immunity without causing autoimmune disease in mice. Cancer Sci (2008) 0.78
Immunization with heat shock protein 105-pulsed dendritic cells leads to tumor rejection in mice. Biochem Biophys Res Commun (2006) 0.78
Generalized fixed drug eruption caused by pazufloxacin. Acta Derm Venereol (2011) 0.78
Risk factors of morbidity and predictors of long-term survival after hepatopancreatoduodenectomy for biliary cancer. Hepatogastroenterology (2015) 0.78
Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells. Cancer Sci (2005) 0.77
[Assessment of serum GPC3 as a tumor marker for hepatocellular carcinoma and malignant melanoma]. Nihon Rinsho (2010) 0.77
Tuberculosis verrucosa cutis with elevation of circulating T-helper 1 and 17 cells and their reductions after successful treatment. J Dermatol (2011) 0.77
Sarcopenia and American Society of Anesthesiologists Physical Status in the Assessment of Outcomes of Hepatocellular Carcinoma Patients Undergoing Hepatectomy. Acta Med Okayama (2016) 0.77
Surgical rationalization of living donor liver transplantation by abolition of hepatic artery reconstruction under a fixed microscope. Clin Transplant (2012) 0.76
Connexin 26 (GJB2) mutations in keratitis-ichthyosis-deafness syndrome presenting with squamous cell carcinoma. J Dermatol (2011) 0.76
Risk factors for primary open-angle glaucoma in Japanese subjects attending community health screenings. Clin Ophthalmol (2011) 0.76
Bloodless donor hepatectomy in living donor liver transplantation: counterclockwise liver rotation and early hanging maneuver. J Gastrointest Surg (2012) 0.76
Toxic epidermal necrosis-like dermatosis induced by the first course of methotrexate. Eur J Dermatol (2009) 0.76
Head and neck cancer antigens recognized by the humoral immune system. Biochem Biophys Res Commun (2002) 0.76
Doripenem-induced intertriginous drug eruption as a mild form of AGEP. J Eur Acad Dermatol Venereol (2009) 0.75
Enhancement of Programmed Death Ligand 2 on Hepatitis C Virus Infected Hepatocytes by Calcineurin Inhibitors. Transplantation (2015) 0.75
Structural changes in the lacrimal sac epithelium and associated lymphoid tissue during experimental dacryocystitis. Clin Ophthalmol (2011) 0.75